Anti-annexin A4 antibody as a biomarker for desquamative interstitial pneumonia

IF 7.9 1区医学 Q1 IMMUNOLOGY

Journal of autoimmunity Pub Date : 2025-03-28 DOI:10.1016/j.jaut.2025.103409

Noriho Sakamoto , Minoru Satoh , Kaname Ohyama , Nozomi Aibara , Yasuhiko Yamano , Yasuhiro Kondoh , Shimpei Morimoto , Mari Yamasue , Kosaku Komiya , Yoshiaki Kinoshita , Hiroshi Ishii , Masaki Fujita , Shigehisa Yanagi , Toshimasa Shimizu , Kiyoyasu Fukushima , Yoshiko Akiyama , Ritsuko Murakami , Takatomo Tokito , Daisuke Okuno , Mutsumi Ozasa , Hiroshi Mukae

{"title":"Anti-annexin A4 antibody as a biomarker for desquamative interstitial pneumonia","authors":"Noriho Sakamoto , Minoru Satoh , Kaname Ohyama , Nozomi Aibara , Yasuhiko Yamano , Yasuhiro Kondoh , Shimpei Morimoto , Mari Yamasue , Kosaku Komiya , Yoshiaki Kinoshita , Hiroshi Ishii , Masaki Fujita , Shigehisa Yanagi , Toshimasa Shimizu , Kiyoyasu Fukushima , Yoshiko Akiyama , Ritsuko Murakami , Takatomo Tokito , Daisuke Okuno , Mutsumi Ozasa , Hiroshi Mukae","doi":"10.1016/j.jaut.2025.103409","DOIUrl":null,"url":null,"abstract":"<div><div>Desquamative interstitial pneumonia (DIP), a rare type of idiopathic interstitial pneumonia (IIP), is smoking-related. However, some cases of DIP can also occur in non-smokers with autoimmune disorders. The diagnosis of DIP requires an invasive surgical lung biopsy, therefore, identifying a non-invasive diagnostic biomarker for DIP is crucial. This study aimed to elucidate autoantibodies specific for DIP and evaluate their diagnostic utility. Autoantibodies in the sera of patients with DIP were screened using immunoprecipitation. The common proteins recognized by autoantibodies in patients with DIP were identified using mass spectrometry and enzyme-linked immunosorbent assay (ELISA), and compared to other types of interstitial lung diseases (ILD) and pulmonary diseases. Several characteristic proteins commonly recognized by the sera of patients with DIP were revealed using immunoprecipitation and these proteins were identified as annexin A (ANXA) proteins using mass spectrometry. Using ELISA, autoantibodies to several ANXA were detected more frequently and specifically in DIP compared with those with other types of ILDs and pulmonary diseases. In particular, anti-ANXA4 antibodies had a sensitivity of 52.6 % and specificity of 99 % for DIP compared with those of other types of ILD. Therefore, anti-ANXAs antibodies, especially anti-ANXA4, could be a candidate diagnostic biomarker for DIP.</div></div>","PeriodicalId":15245,"journal":{"name":"Journal of autoimmunity","volume":"153 ","pages":"Article 103409"},"PeriodicalIF":7.9000,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of autoimmunity","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S089684112500054X","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Desquamative interstitial pneumonia (DIP), a rare type of idiopathic interstitial pneumonia (IIP), is smoking-related. However, some cases of DIP can also occur in non-smokers with autoimmune disorders. The diagnosis of DIP requires an invasive surgical lung biopsy, therefore, identifying a non-invasive diagnostic biomarker for DIP is crucial. This study aimed to elucidate autoantibodies specific for DIP and evaluate their diagnostic utility. Autoantibodies in the sera of patients with DIP were screened using immunoprecipitation. The common proteins recognized by autoantibodies in patients with DIP were identified using mass spectrometry and enzyme-linked immunosorbent assay (ELISA), and compared to other types of interstitial lung diseases (ILD) and pulmonary diseases. Several characteristic proteins commonly recognized by the sera of patients with DIP were revealed using immunoprecipitation and these proteins were identified as annexin A (ANXA) proteins using mass spectrometry. Using ELISA, autoantibodies to several ANXA were detected more frequently and specifically in DIP compared with those with other types of ILDs and pulmonary diseases. In particular, anti-ANXA4 antibodies had a sensitivity of 52.6 % and specificity of 99 % for DIP compared with those of other types of ILD. Therefore, anti-ANXAs antibodies, especially anti-ANXA4, could be a candidate diagnostic biomarker for DIP.

查看原文本刊更多论文

抗膜联蛋白A4抗体作为脱屑性间质性肺炎的生物标志物

脱屑性间质性肺炎（DIP）是一种罕见的特发性间质性肺炎（IIP），与吸烟有关。然而，一些DIP病例也可能发生在患有自身免疫性疾病的非吸烟者身上。DIP的诊断需要侵入性手术肺活检，因此，确定DIP的非侵入性诊断生物标志物是至关重要的。本研究旨在阐明DIP特异性自身抗体并评估其诊断价值。采用免疫沉淀法筛选DIP患者血清中的自身抗体。使用质谱法和酶联免疫吸附试验（ELISA）鉴定DIP患者自身抗体识别的常见蛋白质，并与其他类型的间质性肺疾病（ILD）和肺部疾病进行比较。免疫沉淀法发现DIP患者血清中常见的几种特征蛋白，质谱法鉴定为膜联蛋白A （ANXA）蛋白。ELISA检测结果显示，与其他类型的ILDs和肺部疾病相比，DIP中几种ANXA自身抗体的检测频率和特异性更高。特别是，与其他类型的ILD相比，抗anxa4抗体对DIP的敏感性为52.6%，特异性为99%。因此，抗anxas抗体，特别是抗anxa4抗体，可能是DIP的候选诊断生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of autoimmunity 医学-免疫学

CiteScore

27.90

自引率

1.60%

发文量

117

审稿时长

17 days

期刊介绍： The Journal of Autoimmunity serves as the primary publication for research on various facets of autoimmunity. These include topics such as the mechanism of self-recognition, regulation of autoimmune responses, experimental autoimmune diseases, diagnostic tests for autoantibodies, as well as the epidemiology, pathophysiology, and treatment of autoimmune diseases. While the journal covers a wide range of subjects, it emphasizes papers exploring the genetic, molecular biology, and cellular aspects of the field. The Journal of Translational Autoimmunity, on the other hand, is a subsidiary journal of the Journal of Autoimmunity. It focuses specifically on translating scientific discoveries in autoimmunity into clinical applications and practical solutions. By highlighting research that bridges the gap between basic science and clinical practice, the Journal of Translational Autoimmunity aims to advance the understanding and treatment of autoimmune diseases.